Effect of Pre- and In-Hospital Delay on Reperfusion in Acute Ischemic Stroke Mechanical Thrombectomy.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 17 9 2020
medline: 11 11 2020
entrez: 16 9 2020
Statut: ppublish

Résumé

Post hoc analyses of randomized controlled clinical trials evaluating mechanical thrombectomy have suggested that admission-to-groin-puncture (ATG) delays are associated with reduced reperfusion rates. Purpose of this analysis was to validate this association in a real-world cohort and to find associated factors and confounders for prolonged ATG intervals. Patients included into the BEYOND-SWIFT cohort (Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the Solitaire FR With the Intention for Thrombectomy; https://www.clinicaltrials.gov; Unique identifier: NCT03496064) were analyzed (n=2386). Association between baseline characteristics and ATG was evaluated using mixed linear regression analysis. The effect of increasing symptom-onset-to-admission and ATG intervals on successful reperfusion (defined as Thrombolysis in Cerebral Infarction [TICI] 2b-3) was evaluated using logistic regression analysis adjusting for potential confounders. Median ATG was 73 minutes. Prolonged ATG intervals were associated with the use of magnetic resonance imaging (+19.1 [95% CI, +9.1 to +29.1] minutes), general anesthesia (+12.1 [95% CI, +3.7 to +20.4] minutes), and borderline indication criteria, such as lower National Institutes of Health Stroke Scale, late presentations, or not meeting top-tier early time window eligibility criteria (+13.8 [95% CI, +6.1 to +21.6] minutes). There was a 13% relative odds reduction for TICI 2b-3 (adjusted odds ratio [aOR], 0.87 [95% CI, 0.79-0.96]) and TICI 2c/3 (aOR, 0.87 [95% CI, 0.79-0.95]) per hour ATG delay, while the reduction of TICI 2b-3 per hour increase symptom-onset-to-admission was minor (aOR, 0.97 [95% CI, 0.94-0.99]) and inconsistent regarding TICI 2c/3 (aOR, 0.99 [95% CI, 0.97-1.02]). After adjusting for identified factors associated with prolonged ATG intervals, the association of ATG delay and lower rates of TICI 2b-3 remained tangible (aOR, 0.87 [95% CI, 0.76-0.99]). There is a great potential to reduce ATG, and potential targets for improvement can be deduced from observational data. The association between in-hospital delay and reduced reperfusion rates is evident in real-world clinical data, underscoring the need to optimize in-hospital workflows. Given the only minor association between symptom-onset-to-admission intervals and reperfusion rates, the causal relationship of this association warrants further research. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03496064.

Sections du résumé

BACKGROUND AND PURPOSE
Post hoc analyses of randomized controlled clinical trials evaluating mechanical thrombectomy have suggested that admission-to-groin-puncture (ATG) delays are associated with reduced reperfusion rates. Purpose of this analysis was to validate this association in a real-world cohort and to find associated factors and confounders for prolonged ATG intervals.
METHODS
Patients included into the BEYOND-SWIFT cohort (Bernese-European Registry for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the Solitaire FR With the Intention for Thrombectomy; https://www.clinicaltrials.gov; Unique identifier: NCT03496064) were analyzed (n=2386). Association between baseline characteristics and ATG was evaluated using mixed linear regression analysis. The effect of increasing symptom-onset-to-admission and ATG intervals on successful reperfusion (defined as Thrombolysis in Cerebral Infarction [TICI] 2b-3) was evaluated using logistic regression analysis adjusting for potential confounders.
RESULTS
Median ATG was 73 minutes. Prolonged ATG intervals were associated with the use of magnetic resonance imaging (+19.1 [95% CI, +9.1 to +29.1] minutes), general anesthesia (+12.1 [95% CI, +3.7 to +20.4] minutes), and borderline indication criteria, such as lower National Institutes of Health Stroke Scale, late presentations, or not meeting top-tier early time window eligibility criteria (+13.8 [95% CI, +6.1 to +21.6] minutes). There was a 13% relative odds reduction for TICI 2b-3 (adjusted odds ratio [aOR], 0.87 [95% CI, 0.79-0.96]) and TICI 2c/3 (aOR, 0.87 [95% CI, 0.79-0.95]) per hour ATG delay, while the reduction of TICI 2b-3 per hour increase symptom-onset-to-admission was minor (aOR, 0.97 [95% CI, 0.94-0.99]) and inconsistent regarding TICI 2c/3 (aOR, 0.99 [95% CI, 0.97-1.02]). After adjusting for identified factors associated with prolonged ATG intervals, the association of ATG delay and lower rates of TICI 2b-3 remained tangible (aOR, 0.87 [95% CI, 0.76-0.99]).
CONCLUSIONS
There is a great potential to reduce ATG, and potential targets for improvement can be deduced from observational data. The association between in-hospital delay and reduced reperfusion rates is evident in real-world clinical data, underscoring the need to optimize in-hospital workflows. Given the only minor association between symptom-onset-to-admission intervals and reperfusion rates, the causal relationship of this association warrants further research. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03496064.

Identifiants

pubmed: 32933420
doi: 10.1161/STROKEAHA.120.030208
pmc: PMC7523579
doi:

Banques de données

ClinicalTrials.gov
['NCT03496064']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2934-2942

Références

J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):910-917
pubmed: 29519899
Cerebrovasc Dis. 2017;44(5-6):344-350
pubmed: 29130956
Cerebrovasc Dis. 2016;42(3-4):170-7
pubmed: 27111086
Stroke. 2017 Feb;48(2):348-352
pubmed: 28034965
Clin Neuroradiol. 2017 Mar;27(1):3-5
pubmed: 28124072
Stroke. 2019 Feb;50(2):365-372
pubmed: 30612537
Stroke. 2019 Mar;50(3):659-664
pubmed: 30744542
JAMA Neurol. 2019 Apr 1;76(4):405-411
pubmed: 30667465
J Neurol. 2019 Mar;266(3):598-608
pubmed: 30617997
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Sci Rep. 2017 Nov 21;7(1):15938
pubmed: 29162921
J Neurointerv Surg. 2019 May;11(5):433-438
pubmed: 30194109
J Neurointerv Surg. 2018 Dec;10(12):e30
pubmed: 29760012
Stroke. 2013 Oct;44(10):2802-7
pubmed: 23908066
Radiology. 2003 Jul;228(1):126-30
pubmed: 12728185
Stroke. 2017 Nov;48(11):3152-3155
pubmed: 29018132
J Neurointerv Surg. 2018 Apr;10(4):335-339
pubmed: 28754806
J Neurointerv Surg. 2019 Jan;11(1):9-13
pubmed: 29802163
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012

Auteurs

Johannes Kaesmacher (J)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.
University Institute of Diagnostic and Interventional and Pediatric Radiology (J.K.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Basel Maamari (B)

Department of Neurology (B.M., T.R.M., M.G., M.A., U.F.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Thomas R Meinel (TR)

Department of Neurology (B.M., T.R.M., M.G., M.A., U.F.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Eike I Piechowiak (EI)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Pascal J Mosimann (PJ)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Pasquale Mordasini (P)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Martina Goeldlin (M)

Department of Neurology (B.M., T.R.M., M.G., M.A., U.F.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Marcel Arnold (M)

Department of Neurology (B.M., T.R.M., M.G., M.A., U.F.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Tomas Dobrocky (T)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Tobias Boeckh-Behrens (T)

Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University Munich, Germany (T.B.-B., M.B.).

Maria Berndt (M)

Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University Munich, Germany (T.B.-B., M.B.).

Patrik Michel (P)

Department of Neurology, CHUV Lausanne, Switzerland (P. Michel).

Manuel Requena (M)

Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain (M.R.).

Amel Benali (A)

Department of Neuroradiology, CHU Montpellier, France (A. Benali).

Laurent Pierot (L)

Department of Neuroradiology, CHU Reims, France (L.P.).

Vitor Mendes Pereira (V)

Joint Department of Medical Imaging and Division of Neurosurgery, Toronto Western Hospital, University of Toronto, ON, Canada (V.M.P.).

Grégoire Boulouis (G)

Department of Neuroradiology, Université Paris Descartes, Sainte Anne Hospital, France (G.B.).

Alex Brehm (A)

Department of Neuroradiology (A. Brehm, P.B.S.), University Hospital Basel, Switzerland.

Peter B Sporns (PB)

Department of Neuroradiology (A. Brehm, P.B.S.), University Hospital Basel, Switzerland.

Johanna M Ospel (JM)

Department of Radiology (J.M.O.), University Hospital Basel, Switzerland.
Department of Clinical Neuroscience, University of Calgary, Canada (J.M.O.).

Jan Gralla (J)

University Institute of Diagnostic and Interventional Neuroradiology (J.K., E.I.P., P.J.M., P. Mordasini, T.D., J.G.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Urs Fischer (U)

Department of Neurology (B.M., T.R.M., M.G., M.A., U.F.), University Hospital Bern, Inselspital, University of Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH